Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1992 1
1993 1
1999 1
2002 1
2003 1
2004 1
2005 2
2006 2
2007 1
2008 1
2009 3
2010 6
2011 15
2012 16
2013 8
2014 2
2015 2
2016 5
2017 2
2018 8
2019 5
2020 9
2021 8
2022 1
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Reply to Childs et al.
Gervasoni C, Meraviglia P, Cattaneo D. Gervasoni C, et al. Among authors: meraviglia p. Clin Infect Dis. 2020 Nov 5;71(8):2023. doi: 10.1093/cid/ciaa659. Clin Infect Dis. 2020. PMID: 32459828 No abstract available.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
When the absence of an interaction can become clinically relevant.
Cattaneo D, Bernacchia D, Beltrami M, Resnati C, Meraviglia P, Gervasoni C. Cattaneo D, et al. Among authors: meraviglia p. AIDS. 2021 Jul 1;35(8):1327-1328. doi: 10.1097/QAD.0000000000002878. AIDS. 2021. PMID: 34076620 No abstract available.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016.
Rossetti B, Di Giambenedetto S, Torti C, Postorino MC, Punzi G, Saladini F, Gennari W, Borghi V, Monno L, Pignataro AR, Polilli E, Colafigli M, Poggi A, Tini S, Zazzi M, De Luca A; Antiviral Response Cohort Analysis (ARCA) Collaborative Group. Rossetti B, et al. HIV Med. 2018 Oct;19(9):619-628. doi: 10.1111/hiv.12640. Epub 2018 Jun 22. HIV Med. 2018. PMID: 29932313 Free article.
Determinants of bone diseases in tenofovir-treated HIV patients.
Gervasoni C, Minisci D, Meraviglia P, Baldelli S, Clementi E, Rizzardini G, Cattaneo D. Gervasoni C, et al. Among authors: meraviglia p. AIDS. 2016 Jun 19;30(10):1686-7. doi: 10.1097/QAD.0000000000001094. AIDS. 2016. PMID: 27243779 Free article. No abstract available.
96 results